ProPhase Labs (NASDAQ:PRPH) Upgraded by Wall Street Zen to Hold Rating

ProPhase Labs (NASDAQ:PRPH) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

ProPhase Labs Price Performance

Shares of PRPH opened at $0.43 on Friday. ProPhase Labs has a fifty-two week low of $0.22 and a fifty-two week high of $2.83. The company has a market capitalization of $18.01 million, a price-to-earnings ratio of -0.34 and a beta of -0.78. The firm has a 50-day simple moving average of $0.37 and a 200-day simple moving average of $0.36. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.93 and a current ratio of 0.96.

ProPhase Labs (NASDAQ:PRPH) last announced its earnings results on Wednesday, August 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. The business had revenue of $1.25 million for the quarter, compared to analyst estimates of $3.55 million. On average, equities research analysts anticipate that ProPhase Labs will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On ProPhase Labs

A number of hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in ProPhase Labs in the second quarter valued at about $40,000. Sykon Capital LLC acquired a new stake in ProPhase Labs in the second quarter valued at about $252,000. Josh Arnold Investment Consultant LLC acquired a new stake in ProPhase Labs in the first quarter valued at about $100,000. Citizens Financial Group Inc. RI acquired a new stake in ProPhase Labs in the first quarter valued at about $109,000. Finally, Cerity Partners LLC acquired a new stake in ProPhase Labs in the first quarter valued at about $38,000. Institutional investors and hedge funds own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.